Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting

Launched by UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTRE · Jan 19, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to deliver a local anesthetic called lignocaine using a microneedle patch. The aim is to see if this method can reduce pain for adults who need to have their veins punctured for blood tests before eye surgeries like cataract or glaucoma procedures. The microneedle patch is designed to be safe and biodegradable, allowing the anesthetic to be absorbed more effectively through the skin compared to a standard patch known as EMLA. The researchers will also check how well the anesthetic gets into the bloodstream and compare the effectiveness of both methods in reducing pain.

To participate in this trial, you need to be at least 18 years old and require a blood test before your eye surgery. However, if you have a history of allergic reactions to lignocaine or certain materials used in this study, or if you have certain medical conditions, you may not be eligible. Participants will receive either the microneedle patch or the standard EMLA patch, and the study will focus on measuring pain levels during the procedure. This trial is important because it could lead to better pain management options for patients undergoing necessary medical procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years old and above
• • Patients requiring venous cannulation for blood investigations before eye surgery
• Exclusion Criteria:
• • Patient with a previous history of sensitization or allergy to lignocaine.
• • Patient with a previous history of allergy to materials used in the study i.e., plaster, electrodes, maltose, Polyvinyl Alcohol (PVA), and Polyethylene Terephthalate (PET)
• • Patient exposed to analgesic usage within 24 hours prior to the procedure
• • Generalized skin disorder/ rash
• • Agitated/ fretful / uncooperative patient
• • Uncommunicative/deaf/mute patients
• • Patients on hypnotics, or chronic pain relief medications
• • Patients with psychiatric conditions
• • Patients with hepatic impairment
• • Patients who are on CYP450 3A4, 3A5 or 1A2-inducing or inhibiting drugs (erythromycin, ciprofloxacin, amiodarone etc.) or pharmacotherapeutic agents that affect hepatic blood flow (metoprolol) since both may affect the metabolism of lignocaine